JPMorgan says this new player in the GLP-1 market could rally 45%

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

JPMorgan says this new player in the GLP-1 market could rally 45%

This is the hidden content, please

• Sign In
• or
• Sign Up

-2735 , which would join the likes and rival peer GLP-1 drugs from Novo Nordisk and Eli Lilly , through clinical trials. In July, Viking said an injectable version of the ***** would enter a phase 3 trial, while a phase 2 study of an ***** version is about to begin. Investors are awaiting more details about the ***** version, expected in early November, as a possible catalyst for the stock. Shares have advanced more than 204% in 2024. VKTX YTD mountain Viking Therapeutics stock. “Given investor sentiment on obesity assets, we expect shares to move up substantially on the back of this dataset,” analyst Hardik Parikh wrote in a note Wednesday. “We think this profile should give VKTX a role in the market despite significant long-term barriers (mfg requirements, intense competition) for its ***** and even more for the subQ [subcutaneous] version.” Parikh expects Viking’s results to show that patients are able to tolerate the ***** better than existing drugs such as Novo’s Wegovy and Eli Lilly’s Zepbound. Some patients who take these popular obesity drugs suffer nausea and gastrointensinal effects that force them to stop treatment. The drugs, which mimic incretins, or gut-derived hormones, slow down digestion and regulate blood sugar levels, making patients feel full longer. Both are administered via a weekly injection, but many patients would prefer to take a pill. ***** drugs also tend to be cheaper and easier to manufacture. JPMorgan forecasts the category could reach annual sales of roughly $120 billion by 2030, with ***** sales accounting for about $30 billion by 2035. The analyst said

This is the hidden content, please

• Sign In
• or
• Sign Up

-2735’s higher dose of up to 100 milligrams could show “slightly better efficacy than competitors with still a very good tolerability profile.”

This is the hidden content, please

• Sign In
• or
• Sign Up

#JPMorgan #player #GLP1 #market #rally

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up